LifeMD, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Powers of Attorney (included on signature page)
POWERS OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Justin Schreiber, Marc Benathen, Maria Stan, Eric Yecies and each of them severally, his or her true and lawful attorney in fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the U.S. Securities and Exchange Commission in connection with this Annual Report on Form 10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys in fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By: | /s/ Justin Schreiber |
|---|---|
| Justin Schreiber | |
| Chief Executive Officer and Chairman of the Board of Directors | |
| (principal executive officer) | |
| Date: | March 10, 2026 |
| By: | /s/ Marc Benathen |
| Marc Benathen | |
| Chief Financial Officer | |
| (principal financial officer) | |
| Date: | March 10, 2026 |
| By: | /s/ Maria Stan |
| Maria Stan | |
| Chief Accounting Officer and Controller | |
| (principal accounting officer) | |
| Date: | March 10, 2026 |
| By: | /s/ Roberto Simon |
| Roberto Simon | |
| Director | |
| Date: | March 10, 2026 |
| By: | /s/ John Strawn |
| John Strawn | |
| Director | |
| Date: | March 10, 2026 |
| By: | /s/ Joseph DiTrolio |
| Joseph DiTrolio, M.D. | |
| Director | |
| Date: | March 10, 2026 |
| By: | /s/ Joan LaRovere |
| Joan LaRovere, M.D. | |
| Director | |
| Date: | March 10, 2026 |
| By: | /s/ Will Febbo |
|---|---|
| Will Febbo | |
| Director | |
| Date: | March 10, 2026 |
| By: | /s/ Calum MacRae |
|---|---|
| Calum MacRae | |
| Director | |
| Date: | March 10, 2026 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025
TABLE OF CONTENTS
| Page | |
| REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PricewaterhouseCoopers LLP PCAOB ID No. 238) | F-2 |
|---|---|
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (Marcum LLP PCAOB ID No. 688) | F-4 |
| CONSOLIDATED FINANCIAL STATEMENTS: | |
| Consolidated Balance Sheets | F-5 |
| Consolidated Statements of Operations | F-6 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-9 to F-37 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.